| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 09/12/2024 | 14:15 | Business Wire | Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients | NASDAQ:LTRN | Lantern Pharma Inc |
| 03/12/2024 | 14:00 | Business Wire | Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC) | NASDAQ:LTRN | Lantern Pharma Inc |
| 26/11/2024 | 14:45 | Business Wire | Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality | NASDAQ:LTRN | Lantern Pharma Inc |
| 19/11/2024 | 14:00 | Business Wire | Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients | NASDAQ:LTRN | Lantern Pharma Inc |
| 07/11/2024 | 22:07 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:LTRN | Lantern Pharma Inc |
| 07/11/2024 | 22:05 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:LTRN | Lantern Pharma Inc |
| 07/11/2024 | 22:05 | Business Wire | Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates | NASDAQ:LTRN | Lantern Pharma Inc |
| 05/11/2024 | 14:00 | Business Wire | Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board | NASDAQ:LTRN | Lantern Pharma Inc |
| 31/10/2024 | 13:00 | Business Wire | Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET | NASDAQ:LTRN | Lantern Pharma Inc |
| 23/10/2024 | 14:45 | Business Wire | Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024 | NASDAQ:LTRN | Lantern Pharma Inc |
| 21/10/2024 | 14:00 | Business Wire | Lantern Pharma to Host & Participate in Two Public Webinars During October | NASDAQ:LTRN | Lantern Pharma Inc |
| 15/10/2024 | 15:07 | Business Wire | Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA | NASDAQ:LTRN | Lantern Pharma Inc |
| 23/09/2024 | 14:00 | Business Wire | Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers | NASDAQ:LTRN | Lantern Pharma Inc |
| 08/08/2024 | 22:01 | Business Wire | Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates | NASDAQ:LTRN | Lantern Pharma Inc |
| 07/08/2024 | 15:31 | Business Wire | Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024 | NASDAQ:LTRN | Lantern Pharma Inc |
| 05/08/2024 | 14:00 | Business Wire | Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort | NASDAQ:LTRN | Lantern Pharma Inc |
| 01/08/2024 | 14:00 | Business Wire | Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET | NASDAQ:LTRN | Lantern Pharma Inc |
| 17/07/2024 | 22:30 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:LTRN | Lantern Pharma Inc |
| 10/07/2024 | 14:30 | Business Wire | Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184 | NASDAQ:LTRN | Lantern Pharma Inc |
| 12/06/2024 | 13:30 | Business Wire | Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284 | NASDAQ:LTRN | Lantern Pharma Inc |
| 11/06/2024 | 06:16 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:LTRN | Lantern Pharma Inc |
| 24/05/2024 | 22:08 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:LTRN | Lantern Pharma Inc |
| 24/05/2024 | 22:06 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:LTRN | Lantern Pharma Inc |
| 13/05/2024 | 07:30 | Business Wire | Oregon Therapeutics et Lantern Pharma lancent une collaboration stratégique dans le domaine de l’intelligence artificielle pour optimiser le développement du XCE853, premier candidat médicament de sa catégorie, un puissant inhibiteur... | NASDAQ:LTRN | Lantern Pharma Inc |
| 09/05/2024 | 22:02 | Business Wire | Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights | NASDAQ:LTRN | Lantern Pharma Inc |
| 06/05/2024 | 09:00 | Business Wire | Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism | NASDAQ:LTRN | Lantern Pharma Inc |
| 02/05/2024 | 13:30 | Business Wire | Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET | NASDAQ:LTRN | Lantern Pharma Inc |
| 24/04/2024 | 14:00 | Business Wire | Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development | NASDAQ:LTRN | Lantern Pharma Inc |
| 22/04/2024 | 14:12 | Business Wire | Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan | NASDAQ:LTRN | Lantern Pharma Inc |
| 18/03/2024 | 21:02 | Business Wire | Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights | NASDAQ:LTRN | Lantern Pharma Inc |